Report Content
Chapter 1 Methodology & Scope
1.1 Market scope and definition
1.2 Base estimates and working
1.3 Forecast parameters
1.4 COVID-19 impact analysis at global level
1.5 Data validation
1.6 Data sources
1.6.1 Primary
1.6.2 Secondary
1.6.2.1 Paid sources
1.6.2.2 Unpaid sources
Chapter 2 Executive Summary
2.1 Animal model industry 3600 synopsis, 2018 - 2032
2.1.1 Business trends
2.1.2 Regional trends
2.1.3 Animal type trends
2.1.4 Technology trends
2.1.5 Application trends
2.1.6 Use trends
2.1.7 End-use trends
Chapter 3 Animal Model Industry Insights
3.1 Industry segmentation
3.2 Industry landscape, 2018 – 2032 (USD Million)
3.3 Industry impact forces
3.3.1 Growth drivers
3.3.1.1 Growing number of pharmaceutical research and development activities
3.3.1.2 Increasing application areas of animal model in different research areas
3.3.1.3 Physiological similarities between human and animal
3.3.1.4 Emergence of CRISPR as a powerful tool in the field of biomedical research
3.3.1.5 Growing consumption of personalized medicine driving the demand for humanized mice models
3.3.2 Industry pitfalls & challenges
3.3.2.1 High maintenance cost of animal models
3.3.2.2 Strict regulations and guidelines
3.3.2.3 Growing opposition on animal testing by several organizations
3.4 Growth potential analysis
3.4.1 By animal type
3.4.2 By technology
3.4.3 By application
3.4.4 By use
3.4.5 By end-use
3.5 COVID-19 impact analysis
3.6 Regulatory landscape
3.6.1 U.S.
3.6.2 Europe
3.6.3 Asia Pacific
3.6.4 Latin America
3.6.5 Middle East & Africa
3.7 Pricing analysis, 2022
3.8 Porter’s analysis
3.9 PESTEL analysis
Chapter 4 Competitive Landscape, 2022
4.1 Introduction
4.2 Company matrix analysis
4.3 Competitive analysis of major market players, 2022
4.4 Competitive positioning matrix
4.5 Strategic outlook matrix
4.6 Strategy dashboard
Chapter 5 Animal Model Market Estimates & Forecast, By Animal Type (USD Million & Units)
5.1 Key trends, animal type
5.2 Mice
5.3 Rats
5.4 Fish
5.5 Birds
5.6 Cattle
5.7 Pigs
5.8 Amphibians
5.9 Guinea Pigs
5.10 Dogs
5.11 Cats
5.12 Rabbits
5.13 Monkeys
5.14 Sheep
5.15 Hamsters
5.16 Other animal types
Chapter 6 Animal Model Market Estimates & Forecast, By Technology (USD Million)
6.1 Key trends, technology
6.2 CRISPR
6.3 Microinjection
6.4 Embryonic Stem Cell Injection
6.5 Nuclear Transfer
6.6 Other technologies
Chapter 7 Animal Model Market Estimates & Forecast, By Application (USD Million)
7.1 Key trends, application
7.2 Research & Development
7.2.1 Infectious Diseases
7.2.2 Immunological Diseases
7.2.3 Cancer
7.2.4 Cardiovascular Diseases
7.2.5 Diabetes
7.2.6 Genetic Diseases
7.2.7 Neurological Diseases
7.2.8 Obesity
7.2.9 NAFLD/NASH
7.2.10 Renal disease
7.2.11 Diabetic eye disease
7.2.12 Fibrosis
7.2.13 Microbiome
7.2.14 Other research & development applications
7.3 Production and Quality Control
7.4 Academics
7.5 Preclinical Applications
7.5.1 Infectious Disease
7.5.2 Immunological Diseases
7.5.3 Cancer
7.5.4 Cardiovascular Diseases
7.5.5 Diabetes
7.5.6 Genetic Diseases
7.5.7 Neurological Diseases
7.5.8 Obesity
7.5.9 NAFLD/NASH
7.5.10 Renal disease
7.5.11 Diabetic eye disease
7.5.12 Fibrosis
7.5.13 Microbiome
7.5.14 Other preclinical applications
7.6 Other applications
Chapter 8 Animal Model Market Estimates & Forecast, By Use (USD Million)
8.1 Key trends, use
8.2 Human
8.2.1 Market estimates and forecast, 2018 - 2032 (USD Million)
8.3 Veterinary
8.3.1 Market estimates and forecast, 2018 - 2032 (USD Million)
Chapter 9 Animal Model Market Estimates & Forecast, By End-use (USD Million)
9.1 Key trends, end-use
9.2 Companies
9.2.1 Pharmaceutical
9.2.2 Biotechnology
9.2.3 Cosmetics
9.2.4 Other companies
9.3 Organizations
9.3.1 Government
9.3.2 Non-government
9.4 Academic & Research Institutes
9.5 Contract Research Organizations
Chapter 10 Animal Model Market Estimates & Forecast, By Region (USD Million)
10.1 Key trends, region
10.2 North America
10.2.1 U.S.
10.2.2 Canada
10.3 Europe
10.3.1 Germany
10.3.2 UK
10.3.3 France
10.3.4 Spain
10.3.5 Italy
10.3.6 Switzerland
10.3.7 Netherlands
10.3.8 Czech Republic
10.3.9 Poland
10.3.10 Belgium
10.3.11 Finland
10.3.12 Hungary
10.3.13 Denmark
10.3.14 Ireland
10.3.15 Sweden
10.4 Asia Pacific
10.4.1 China
10.4.2 Japan
10.4.3 Australia
10.4.4 South Korea
10.4.5 New Zealand
10.4.6 Taiwan
10.5 Latin America
10.5.1 Brazil
10.5.2 Argentina
10.5.3 Mexico
10.6 Middle East & Africa
10.6.1 South Africa
10.6.2 Saudi Arabia
10.6.3 UAE
10.6.4 Israel
Chapter 11 Company Profiles
11.1 Charles River Laboratories
11.2 Envigo
11.3 genOway
11.4 Harbour BioMed
11.5 Janvier Labs
11.6 PharmaLegacy
11.7 Taconic Biosciences Inc.
11.8 The Jackson Laboratory
11.9 TRANS GENIC INC, Ltd.
